Connect with us

Coronavirus Outbreak

COVID-19: Covaxin “Effectively Neutralises” Delta Variant, Says Top US Health Institute

The National Institute of Health said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2

COVID-19: Covaxin "Effectively Neutralises" Delta Variant, Says Top US Health Institute
Highlights
  • Covaxin comprises disabled form of SARS-CoV-2 that stimulates immune system
  • Ending a global pandemic requires a global response: Anthony S Fauci
  • Bharat Biotech expects to produce 700 million doses of Covaxin this year

Washington: India’s Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, the US’ National Institute of Health has said. The NIH said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively.

Also Read: Cipla Gets DCGI Nod To Import Moderna’s Covid Vaccine For Restricted Emergency Use In India: Sources

The top American health research institute, which has a history of strong scientific collaboration with India, also said that an adjuvant developed with funding from it has contributed to the success of the highly efficacious Covaxin, which has been administered to roughly 25 million people till date in India and elsewhere.

Adjuvants are substances formulated as part of a vaccine to boost immune responses and enhance a vaccine’s effectiveness.

Covaxin comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus. Published results from a phase 2 trial of the vaccine indicate that it is safe and well tolerated, the NIH said, adding that safety data from a phase 3 trial of Covaxin will become available later this year.

Meanwhile, unpublished interim results from the phase 3 trial indicate that the vaccine has 78 per cent efficacy against symptomatic disease, 100 per cent efficacy against severe COVID-19, including hospitalisation, and 70 per cent efficacy against asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19, it said.

“The results from two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively,” the NIH said.

Also Read: Zydus Cadila’s COVID-19 Vaccine For Children Over 12 Years Expected By August: National Technical Advisory Group on Immunisation Chief

Ending a global pandemic requires a global response, said Anthony S Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH.

I am pleased that a novel vaccine adjuvant developed in the US with NIAID support is part of an efficacious COVID-19 vaccine available to people in India, he said.

The adjuvant used in Covaxin, Alhydroxiquim-II, was discovered and tested in a laboratory by the biotech company ViroVax LLC of Lawrence, Kansas with support from the NIAID Adjuvant Development Program.

Alhydroxiquim-II is the first adjuvant in an authorised vaccine against an infectious disease to activate receptors TLR7 and TLR8 that play a vital role in the immune response to viruses.

In addition, the alum in Alhydroxiquim-II stimulates the immune system to search for an invading pathogen. Molecules that activate TLR receptors stimulate the immune system powerfully, but the side effects of Alhydroxiquim-II are mild, the NIH said.

According to the NIH, the NIAID Adjuvant Program has supported the research of the founder and chief executive officer of ViroVax, Sunil David, MD, PhD, since 2009. His work has focused on searching for novel molecules that activate innate immune receptors and developing them as vaccine adjuvants.

Also Read: Availability Of COVID Vaccine For Kids Will Pave Way For School Reopening: AIIMS Chief

The collaboration between Dr David and Bharat Biotech International Ltd. of Hyderabad was initiated during a 2019 meeting in India coordinated by the NIAID Office of Global Research under the auspices of NIAID’s Indo-US Vaccine Action Program.

A delegation of five NIAID-funded adjuvant investigators, including Dr David; two members of the NIAID Division of Allergy, Immunology, and Transplantation; and the NIAID India representative, visited four leading biotechnology companies to learn about their work and discuss potential collaborations.

The delegation also attended a consultation in New Delhi co-organised by NIAID and India’s Department of Biotechnology and hosted by India’s National Institute of Immunology.

Among the scientific collaborations sparked by these activities, Bharat Biotech signed a licensing agreement with Dr David to use Alhydroxiquim-II in their candidate vaccines. This license was expanded during the COVID-19 pandemic to include Covaxin, which has received Emergency Use Authorisation in India and more than a dozen other countries.

The company conducted extensive safety studies of Alhydroxiquim-II and undertook the complex process of scaling up production of the adjuvant under Good Manufacturing Practice standards. Bharat Biotech expects to produce an estimated 700 million doses of Covaxin by the end of 2021, the NIH said.

Also Read: COVID Cases With Variants Of Concern Rose From 10% In May To 51% Till June 20: Parliament Panel Told

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene

World

24,29,84,542Cases
20,45,14,204Active
3,35,32,126Recovered
49,38,212Deaths
Coronavirus has spread to 195 countries. The total confirmed cases worldwide are 24,29,84,542 and 49,38,212 have died; 20,45,14,204 are active cases and 3,35,32,126 have recovered as on October 23, 2021 at 3:51 am.

India

3,41,59,562 16,326Cases
1,73,7282,017Active
3,35,32,126 17,677Recovered
4,53,708 666Deaths
In India, there are 3,41,59,562 confirmed cases including 4,53,708 deaths. The number of active cases is 1,73,728 and 3,35,32,126 have recovered as on October 23, 2021 at 2:30 am.

State Details

State Cases Active Recovered Deaths
Maharashtra

65,99,850 1,632

27,747 152

64,32,138 1,744

1,39,965 40

Kerala

48,97,884 9,361

81,490 603

47,88,629 9,401

27,765 563

Karnataka

29,85,227 378

8,920 97

29,38,312 464

37,995 11

Tamil Nadu

26,92,949 1,152

13,531 259

26,43,431 1,392

35,987 19

Andhra Pradesh

20,62,781 478

5,398 102

20,43,050 574

14,333 6

Uttar Pradesh

17,10,069 1

85 22

16,87,085 23

22,899

West Bengal

15,84,492 846

7,577 42

15,57,882 792

19,033 12

Delhi

14,39,526 38

340 29

14,14,095 8

25,091 1

Odisha

10,37,523 467

4,197 139

10,25,025 603

8,301 3

Chhattisgarh

10,05,799 26

214 8

9,92,013 18

13,572

Rajasthan

9,54,396 1

32 4

9,45,410 5

8,954

Gujarat

8,26,378 25

165 9

8,16,126 16

10,087

Madhya Pradesh

7,92,729 8

80 8

7,82,126 16

10,523

Haryana

7,71,133 8

122 9

7,60,962 17

10,049

Bihar

7,26,045 3

30 0

7,16,354 3

9,661

Telangana

6,69,932 193

3,963 4

6,62,025 196

3,944 1

Assam

6,08,126 315

3,866 104

5,98,296 209

5,964 2

Punjab

6,02,163 28

230 4

5,85,382 24

16,551

Jharkhand

3,48,562 36

183 17

3,43,244 19

5,135

Uttarakhand

3,43,799 12

166 10

3,36,235 22

7,398

Jammu And Kashmir

3,31,494 108

870 56

3,26,195 52

4,429

Himachal Pradesh

2,22,312 174

1,483 31

2,17,096 141

3,733 2

Goa

1,77,819 54

600 18

1,73,862 72

3,357

Puducherry

1,27,621 57

454 0

1,25,314 56

1,853 1

Manipur

1,23,107 56

906 440

1,20,294 494

1,907 2

Mizoram

1,16,689 745

9,636 398

1,06,653 1,143

400

Tripura

84,376 7

98 7

83,462 14

816

Meghalaya

83,269 59

698 37

81,128 94

1,443 2

Chandigarh

65,320 5

28 2

64,472 3

820

Arunachal Pradesh

55,075 10

141 1

54,654 9

280

Sikkim

31,842 23

183 2

31,266 25

393

Nagaland

31,689 19

245 5

30,766 23

678 1

Ladakh

20,896

40 3

20,648 3

208

Dadra And Nagar Haveli

10,679 1

4 0

10,671 1

4

Lakshadweep

10,365

0 0

10,314

51

Andaman And Nicobar Islands

7,646

6 1

7,511 1

129

Coronavirus Outbreak: Full CoverageTesting CentresFAQs

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Highlights From The 12-Hour Telethon

Leaving No One Behind

Mental Health

Environment

Join Us